NCT03832179View on ClinicalTrials.gov

Steroid vs. Anti-vascular Endothelial Growth Factor for Diabetic Macular Edema Prior to Phacoemulsification

PHASE4CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

November 15, 2018

Primary Completion Date

September 1, 2023

Study Completion Date

March 30, 2024

Conditions
Diabetic Macular EdemaCataract
Interventions
DRUG

Bevacizumab

Bevacizumab

DRUG

Ranibizumab

Ranibizumab

DRUG

Aflibercept

Aflibercept

DRUG

Ozurdex

Ozurdex

Trial Locations (1)

94598

Bay Area Retina Associates, Walnut Creek

Sponsors

Collaborators (1)

Allergan
All Listed Sponsors
collaborator

Allergan

INDUSTRY

lead

Bay Area Retina Associates

OTHER

NCT03832179 - Steroid vs. Anti-vascular Endothelial Growth Factor for Diabetic Macular Edema Prior to Phacoemulsification | Biotech Hunter | Biotech Hunter